Scholar Rock Holding CORP (SRRK) — Who's Buying and Selling (13F, Q2 2026)

SRRK ranks #2052 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

SRRK is a top-conviction position for Samsara BioCapital, LLC — at 31.2% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in SRRK belongs to FMR LLC, but the position matters far more to Samsara BioCapital, LLC, who has 31.2% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Fidelity has added to its SRRK position for two straight quarters, increasing it by $312.2M to reach $989.7M today.

Bellevue Group AG has trimmed its SRRK position for two straight quarters, cutting it by $44.0M while still holding $134.7M.

SRRK is up 3.1% today, and institutions have been net buyers of $766.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

SRRK reported a net loss of $408.6M over the trailing twelve months.

• Not yet profitable — net loss of $408.6M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$315.7M to -$408.6M
• Operating cash flow was negative, using $300.0M in cash
• Current ratio of 6.95x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.65x equity — within a conventional range